Johnson & Johnson (NYSE: JNJ) reported third-quarter 2021 financial results before the regular market hours on Tuesday.
The pharmaceutical giant reported revenue of $23.3 billion, up 10.7% year-over-year, with operational growth of 9.9%
Net earnings of $3.6 billion or $1.37 per share increased by 3%, also topped the target that analysts had anticipated.